Overview:
There has been more noise about MSK acquisitions in the last two years than in the previous twenty. Most clinicians still misunderstand what M&A actually is, what private equity is, and why so many clinics are suddenly being bought. In this episode, Michael Schumacher speaks with Claire and Yoni, co-CEOs of Kinetico Health, one of the most active buyers in the sector. They talk openly about acquisitions, valuations, culture, patient care, competition, and the long-term future of MSK.
Show Notes:Kinetico Health didn’t come from healthcare. Claire and Yoni both worked in high-level finance before leaving to build something with more purpose. Two years later, they have four clinics in their group and are targeting 40 across the UK. Their model is simple: buy strong clinics, preserve their culture, take over the operational load, and grow them.
In this episode, they walk Michael through the parts of M&A that most clinic owners never hear about:
• Why private equity is misunderstood and why Kinetico is not private equity
• How they differ from “fund-led rollups” that act at a distance and swap CEOs when things go wrong
• Why they stay involved operationally and know every practitioner by name
• Why they refuse to strip clinics of their identity, branding or local culture
• What sellers actually get when they sell: capital, support, stability and less stress
They also address the big fears in the sector:
• Does M&A harm care quality?
• Will corporates push quick wins and short-term profit?
• Will small clinics be outspent or squeezed out?
Their view is blunt: good care is the only sustainable model, large clinics run more efficiently than tiny ones, and competition forces everyone to raise standards. They make the case that investment brings better facilities, more staff, stronger systems, and better outcomes — not worse.
Michael pushes them on the controversial topics:
• Whether consolidation can damage innovation
• How groups should collaborate rather than isolate
• Why some valuations in the market are delusional
• Whether today’s high multiples are sustainable
• Why many clinic owners overestimate what their business is worth
Claire breaks down valuations in practical terms: adjusted EBITDA, how multiples work, what increases or decreases value, and why practitioner concentration and stability matter more than most owners realise.
They finish with a discussion on timing. Should owners sell now or wait? With tax changes coming, macro uncertainty rising and multiples inflated, the honest answer is simple: certainty now is often worth more than maybe later.
What You’ll Learn• How M&A actually works in MSK
• Why private equity is misunderstood
• What buyers look for in a clinic
• What really determines valuation (beyond turnover)
• Why consolidation isn’t automatically bad for the profession
• Where smaller clinics can still win
• Why legacy, culture and patient experience matter more than spreadsheets
Who This Episode Is For• Clinic owners considering selling in the next 3–5 years
• Anyone trying to understand valuations and multiples
• Clinicians worried about corporate consolidation
• Owners debating whether to scale or stay independent
• MSK leaders who want clarity rather than rumour
Guest DetailsGuests: Claire & Yoni
Roles: Co-CEOs of Kinetico Health
Background: Investment banking, private equity, consulting, Harvard MBAs
Specialisms: M&A, operations, clinic integration, scaling private healthcare
Group Clinics: Leeds, Tunbridge Wells, Sale, and more planned
Website: https://kineticohealth.com/